ArticleMolecules (Basel, Switzerland)2016
Miracle Fruit (Synsepalum dulcificum) Exhibits as a Novel Anti-Hyperuricaemia Agent.
Article in Molecules (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- Efficacy and Safety of Habitual Consumption of a Food Supplement Containing Miraculin in Malnourished Cancer Patients: The CLINMIR Pilot Study.Nutrients · 2024Trial
- Unveiling the therapeutic benefits of black chokeberry (Frontiers in nutrition · 2025Article
- Anti-Hyperlipidemic Components of the Leaves of Synsepalum dulcificum (Miracle Fruit).Plant foods for human nutrition (Dordrecht, Netherlands) · 2024Article
- Biological Activities of Miracle Berry Supercritical Extracts as Metabolic Regulators in Chronic Diseases.International journal of molecular sciences · 2023Article
- Miracle fruit seed as a potential supplement for the treatment of learning and memory disorders in Alzheimer's disease.Frontiers in pharmacology · 2022Article
- Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- The Chromosome-Level Genome of Miracle Fruit (Frontiers in plant science · 2021Article
- Miracle Berry as a Potential Supplement in the Control of Metabolic Risk Factors in Cancer.Antioxidants (Basel, Switzerland) · 2020Review
- Nutritional benefits, phytochemical constituents, ethnomedicinal uses and biological properties of Miracle fruit plant (Heliyon · 2020Review
- Complete chloroplast genome ofMitochondrial DNA. Part B, Resources · 2020Article
- The Efficacy and Mechanism of Chinese Herbal Medicines in Lowering Serum Uric Acid Levels: A Systematic Review.Frontiers in pharmacology · 2020Article
- Antihyperuricemic effect of mangiferin aglycon derivative J99745 by inhibiting xanthine oxidase activity and urate transporter 1 expression in mice.Acta pharmaceutica Sinica. B · 2018Article
- Anti-gout Potential of Malaysian Medicinal Plants.Frontiers in pharmacology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Miracle fruit (Synsepalum dulcificum) belongs to the Sapotaceae family. It can change flavors on taste buds, transforming acidic tastes to sweet. We evaluated various miracle fruit extracts, including water, butanol, ethyl acetate (EA), and hexane fractions, to determine its antioxidant effects. These extracts isolated from miracle fruit exerted potential for reduction of uric acid and inhibited xanthine oxidase activity in vitro and in monosodiumurate (MSU)-treated RAW264.7 macrophages. Moreover, we also found that the butanol extracts of miracle fruit attenuated oxonic acid potassium salt-induced hyperuricaemia in ICR mice by lowering serum uric acid levels and activating hepatic xanthine oxidase. These effects were equal to those of allopurinol, suggesting that the butanol extract of miracle fruit could be developed as a novel anti-hyperuricaemia agent or health food.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.